UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8‑K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
December 4, 2019
Ra Medical Systems, Inc.
(Exact name of registrant as specified in its charter)
Delaware |
|
001-38677 |
|
38-3661826 |
(State or other jurisdiction of incorporation) |
|
(Commission File Number) |
|
(IRS Employer |
2070 Las Palmas Drive
Carlsbad, California 92011
(Address of principal executive offices, including zip code)
(760) 804-1648
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
Common Stock, par value $0.0001 per share |
|
RMED |
|
New York Stock Exchange |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
On December 4, 2019, Ra Medical Systems, Inc. (the “Company”) was notified by the New York Stock Exchange (the “NYSE”) that it was not in compliance with one of the continued listing standards applicable to the Company.
As required under the NYSE rules, the Company issued a press release on December 6, 2019, announcing that it had received the notice of noncompliance. A copy of this press release is attached as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. |
|
Description |
|
|
|
|
||
|
|
|
|
|
|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
RA MEDICAL SYSTEMS, INC. |
|
|
|
|
|
||||
Date: December 6, 2019 |
|
|
|
|
|
By: |
|
/s/ Daniel Horwood |
|
|
|
|
|
|
|
|
Daniel Horwood General Counsel and Secretary
|
Exhibit 99.1
Ra Medical Systems Receives NYSE Failure to Satisfy a Continued Listing Rule Notification
CARLSBAD, Calif. (December 6, 2019) – Ra Medical Systems, Inc. (NYSE: RMED), a medical device company focusing on commercializing excimer laser systems to treat vascular and dermatological diseases, today announced that on December 4, 2019, it received a notice from the New York Stock Exchange (the “NYSE”) that it is not in compliance with a NYSE continued listing requirement for maintaining an average total market capitalization of not less than $50 million over a period of 30 consecutive trading days and having stockholders’ equity of not less than $50 million.
The Company intends to submit a plan within 45 days of the notice to the NYSE advising how the Company plans to regain compliance with the continued listing standards within 18 months of the receipt of the notice. If NYSE does not accept the plan or the Company is not in compliance with the continued listing standards at the end of such 18 month cure period, or does not make progress consistent with the plan, NYSE may initiate delisting procedures. The NYSE notification does not affect the Company’s business operations or its Securities and Exchange Commission reporting requirements. During this period, the Company’s common stock will continue to be traded on the NYSE, subject to compliance with other continued NYSE listing requirements.
About Ra Medical Systems
Ra Medical Systems commercializes excimer lasers and catheters for the treatment of vascular and dermatological diseases. In May 2017, the DABRA laser system and single-use DABRA catheter received FDA 510(k) clearance in the U.S. as a device for crossing chronic total occlusions, or CTOs, in patients with symptomatic infrainguinal lower extremity vascular disease with an intended use for ablating a channel in occlusive peripheral vascular disease. Pharos excimer laser system is FDA-cleared and is used as a tool in the treatment of psoriasis, vitiligo, atopic dermatitis, and leukoderma. DABRA and Pharos are both based on Ra Medical’s core excimer laser technology platform and deploy similar mechanisms of action. Ra Medical manufactures DABRA and Pharos excimer lasers and catheters in a 32,000-square-foot facility located in Carlsbad, California. The vertically integrated facility is ISO 13485 certified and is licensed by the state of California to manufacture sterile, single-use catheters in controlled environments.
Contacts
At the Company:
Jeffrey Kraws
President, Ra Medical Systems
760-707-7516
jkraws@ramed.com
Investors and Media:
LHA Investor Relations
Jody Cain / Kevin McCabe
310-691-7100
jcain@lhai.com / kmccabe@lhai.com
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end